Genetically engineered strain WSJ-IA for producing isovaleryl spiramycin i

LAP228AUndetermined Publication Date: 2025-03-21SHENYANG TONGLIAN GRP CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
LAP228
Authority / Receiving Office
LA · LA
Patent Type
Applications
Current Assignee / Owner
Priority Date
2010-07-23
Filing Date
2011-07-21
Publication Date
2025-03-21

AI Technical Summary

Technical Problem

The existing technology is difficult to obtain high content and high yield of isovalerylspiramycin I in antibiotic production, resulting in low production efficiency and difficulty in meeting the needs of industrial scale.

Method used

By introducing the linkage of the isovaleryltransferase gene ist and the regulatory gene acyB2 into the isovalerylspiramycin I-producing strain, and using a non-autonomously replicating integrated vector, the expression and production of isovalerylspiramycin I were improved, and PCR verified its integration and expression in the strain.

Benefits of technology

The content and yield of isovalerylspiramycin I are significantly increased, the fermentation unit is increased by 414%, and the component content is increased by 170.2%. It is suitable for industrial production and pharmacodynamic research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
Patent Text Reader

Abstract

A genetically engineered strain WSJ-IA for producing isovaleryl spiramycin I. Also provided is a method for preparing the strain, comprising the steps of: (a) constructing a recombinant plasmid comprising a double gene ist-acyB2; (b) transforming the plasmid into an isovaleryl spiramycin I - producing strain to obtain the strain WSJ-IA. The level of isovaleryl spiramycin I produced by fermentation of the strain WSJ-IA is increased 1.7 times and the fermentation potency thereof increased 4.14 times in comparison with the strain exclusively comprising a single gene ist.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] WSJ-IA, a genetically engineered bacterium used for the production of isovalerylspiramycin I, is a product of the technical field of this invention.

[0002] This invention relates to the construction of strains with high content and high yield of single antibiotic components using regulatory gene technology. Background Art

[0003] Biterspiramycin (formerly known as Biotechycin) [Patent No.: ZL97104440.6] is a derivative produced by combining the isovaleryl transferase gene *ist* of thermostable *Streptomyces* with the genome of spiramycin-producing bacteria, resulting in the esterification of the 4' hydroxyl group of the carboxylic acid by an isovaleryl group. Biterspiramycin exhibits strong activity against Gram-positive bacteria, particularly *Streptococcus pneumoniae*, *Mycoplasma pneumoniae*, and *Chlamydia*. It also shows antibacterial activity against erythromycin and β-lactam antibiotic-resistant bacteria, *Haemophilus influenzae*, *Legionella*, and *Clostridium perfringens*. It does not exhibit complete cross-resistance with similar drugs. It has high lipophilicity, rapid oral absorption, strong tissue penetration, wide distribution, long duration of action in vivo, and good post-antibiotic effects. Phase III clinical trials of the genetically engineered biterspiramycin have been completed, showing good efficacy and safety. Currently, an application for a Class I new drug certificate is being submitted.

[0004] Clinical studies have demonstrated that spiramycin is a safe and effective antibiotic, with efficacy comparable to azithromycin, currently recognized as the best macrolide antibiotic. However, as a multi-component drug, although current tablet manufacturing processes can produce spiramycin with controllable component ratios and stable quality, the extraction and purification processes require high precision, and the quality control process is complex. Furthermore, to improve its clinical efficacy, it is essential to develop an injectable formulation. Injectable formulations are known for their rapid onset of action and are suitable for critically ill patients or those who cannot take oral medication. Naturally, injectable formulations require even higher quality control standards.

[0005] The multicomponent produced by the spiramycin-producing bacteria is derived from spiramycin. Spiramycin is a macrolide antibiotic with a main core consisting of a 16-membered lactone ring, homologous to pralatone, containing three sugar molecules: phosphatamine, carbamosamine, and carbamosaccharide. The main component of spiramycin is a derivative of spiramycin carbamosaccharide with the 4" hydroxyl group esterified by isovaleryl. Because the spiramycin-producing bacteria possess a 3-O-acyltransferase gene, the 3" hydroxyl group of the spiramycin lactone ring can be acetylated to form spiramycin component II; propionylation forms spiramycin component III; and a hydroxyl group at the 3" position of the lactone ring forms spiramycin component I. Therefore, spiramycin at least contains three components: isovalerylspiramycin I, II, and III. The chemical structure of the main component of spiramycin is as follows:

[0007] in:

[0008] Isovalerate Spiramycin III Ri=COCH2R2=COCH2CH(C

[0009] H3)2

[0010] Isovalerate Spiramycin II R,=COCH R2=COCH2CH(C

[0011] H3)2

[0012] Isovalerylspiramycin I R2=COCH2CH(C

[0013] H3)2

[0014] Studies have shown that isovaleryl spiramycin components I, II, and III all possess antibacterial activity, and there is no significant difference in their activity [Patent Application No.: 2010101 19745.1]. According to the current quality standards for spiramycin, isovaleryl spiramycin (I + II + III) should not be less than 60%. Therefore, a single component (content higher than 60%) can be used to replace a multi-component mixture. To reduce the production of multiple components by bacterial strains, our laboratory used gene recombination technology to construct a strain WSJ-2 that produces only isovaleryl spiramycin component I in the spiramycin-producing bacterium WSJ-1 by blocking the 3-O-acyltransferase gene [Chunyan Ma et al. Current].

[0015] [Microbiology, 2011, 62:16-20]. However, the fermentation unit of this strain is very low, which is not conducive to large-scale production. This invention aims to utilize the regulatory gene acyB2 to modify the strain WSJ-2 to increase the content and yield of isovalerylspiramycin I, laying the foundation for the clinical development of the single-component isovalerylspiramycin I, a homologue of bispyribacylspiramycin.

[0016] It is known that the isovaleryltransferase gene ist, derived from thermostable Streptomyces, is linked to the regulatory gene acyB2, and the presence of the regulatory gene can activate the expression of the ist gene. Streptomyces fradiae, a model strain of Streptomyces containing the complete ist and acyB2 regulatory genes, can convert 67-79% of exogenously added tylosin into 4" isovaleryltylosin, while Streptomyces fradiae containing only a single ist or ist with an incomplete acyB2 gene has a tylosin conversion rate of only 0-2.4% [Arisawa A et al: Biosci Biotechnol Biochem 1993, 57 (12): 2020-2025]. When recombinant plasmids containing autonomously replicating forms (pIJ702 or pIJ943 vectors) of the tylosin-producing strain *Streptomyces fradiae* are transformed into transformants, under the condition of drug addition (exogenous thiopeptidase), after fermentation, in addition to mainly producing tylosin, trace amounts of 4" isovaleryltylosin (approximately 56 μg / mL) can be detected [Arisawa A et al.]. al : J Antibiotics 1996,49(4):349-354 ]0 However, to date, no bacterial transformation has been observed in tylosin-producing bacteria. Reports indicate that the acyB2 gene can increase the yield or single-component content of isovaleryl tylosin. The acyB2 regulatory gene is homologous to the transcriptional regulatory protein Srm28c in the spiramycin-producing bacterium *Streptomyces fradiae* [Fatma Karray et al. Microbiology 2007, 153, 4111-4122], with an identity of 69%, and 41% identity with the regulatory protein tylR in the tylosin-producing bacterium *Streptomyces fradiae*. tylR is a positive regulator of tylosin biosynthesis in tylosin-producing bacteria; it regulates the expression of a polyketide synthase module (tylGI) in tylosin and also regulates the synthesis of tylosin glycosyl groups and the oxidation of the polyketide ring. High expression of the tylR gene in producing bacteria can increase tylosin yield [George S. et al. Mol. Microbiology]. 2004, 54(5): 1326-1334]. However, in spiramycin-producing bacteria containing genes homologous to the acyB2 regulatory gene, the method of integrating the ist gene into the spiramycin-producing bacteria using chromosome-recombinant plasmid homologous DNA recombination technology can only produce a mixture of isovalerylspiramycin, with a yield of up to 800 μg / mL [Shang Guangdong et al., Journal of Biotechnology, 1999, 15(2): 171]. This indicates that the ist gene alone, when transferred into strains containing genes similar to the acyB2 regulatory gene, does not significantly increase the yield and component content of the target product.

[0017] Our laboratory has used genetic engineering techniques to tandem the ist gene, increasing its copy number in spiramycin-producing bacteria and enhancing the isovalerylation ability of the producing bacteria by increasing its gene dosage. We have also used promoters with strong initiation activity, such as the erythromycin resistance gene ermE promoter sequence, to replace the original ist gene promoter sequence, thereby enhancing the expression of the ist gene and increasing the content of the main component of isovalerylspiramycin produced by the genetically engineered bacteria by 62% [Patent Application No. 200910148767.8].

[0018] The objective of this invention is to utilize an efficient and stable expression system to express the *ist*-linked gene with the regulatory gene *acyB2* in strains that produce only isovaleryl spiramycin I, thereby obtaining a strain with high content and high yield of the single-component isovaleryl spiramycin I. This requires overcoming the limitations of modifying exogenous genes in antibiotic-producing bacteria with practical value and improving the conversion rate of exogenous DNA. Simultaneously, a stable expression vector system must be selected so that the constructed genetically engineered bacteria are suitable for large-scale industrial production. This invention employs a non-autonomous replication integration vector in *Streptomyces*. This vector contains *Streptomyces* bacteriophage integrase and attachment sites, and contains only *E. coli* replicons, facilitating preparation in *E. coli* while lacking *Streptomyces* replicons. When it enters the *Streptomyces* cell, it integrates with the host bacterium's specific attachment sites via the attachment site (attP) on the vector. Therefore, the exogenous gene can be stably expressed during large-scale production. The study on the co-expression of the isovaleryltransferase gene ist and the regulatory gene acyB2 in isovalerylspiramycin I producing bacteria to improve the content and yield of isovalerylspiramycin I components, as well as the experimental study on pilot-scale production, has not been reported domestically or internationally to date. Summary of the Invention

[0019] 1. This invention provides a genetically engineered bacterium with high content and high yield of isovaleryl spiramycin I component. The engineered bacterium is a clone strain in which the isovaleryl transferase gene ist and the acyB2 regulatory gene are co-expressed in the isovaleryl spiramycin I producing bacterium WSJ-2.

[0020] 2. This invention provides the construction of a strain with high content and high yield of isovalerylspiramycin I component. The construction uses total DNA from *Streptomyces thermotolarences* (CGMCC4.1501) as a template, and primers are designed based on the istacyB2 sequence published by NCBI. PCR is then used to obtain istacyB2. CThe yB2 linked gene fragment was modified by adding appropriate restriction enzyme sites. Alternatively, the ist and acyB2 gene fragments could be ligated separately to an integrative vector capable of being transformed into isovaleryl spiramycin I-producing bacteria using suitable restriction enzyme sites to construct a recombinant plasmid containing the ist-acyB2 gene. The ist-acyB2 recombinant plasmid was transformed into the isovaleryl spiramycin I-producing bacterium WSJ-2, and PCR confirmed the integration of ist-acyB2 into the transformant genome, yielding the isovaleryl spiramycin I-producing bacterium WSJ-IA.

[0021] 3. In accordance with the classification and identification standards of Streptomyces, the characteristics of WSJ-IA strains were identified.

[0022] 4. This invention uses the isovaleryl spiramycin I-producing bacterium WSJ-2 containing the isist single gene as a control to test the fermentation performance of the WSJ-IA strain, including detecting the fermentation titer of the WSJ-IA strain using microbiological methods and quantitatively analyzing the content of isovaleryl spiramycin I in the fermentation broth using HPLC. The results demonstrate that the introduction of the acyB2 regulatory gene can significantly increase the content and yield of isovaleryl spiramycin I produced by the strain.

[0023] Invention Effects: The positive effects of this invention are that it demonstrates that introducing the acyB2 regulatory gene into the isovaleryl spiramycin I-producing strain WSJ-2 can increase the fermentation unit of the producing strain by 414% and increase the content of isovaleryl spiramycin component I by 170.2%. The high-yield isovaleryl spiramycin I strain constructed in this invention has been pilot-scale tested in a 2-ton fermenter, and the samples accumulated for isovaleryl spiramycin I have entered the pharmacodynamic study stage. The application of this strain not only facilitates the simplification of quality control and testing standards for the industrial production of single-component antibiotics, but also creates conditions for the preparation of isovaleryl spiramycin injection formulations. (See attached figures for details.)

[0024] Figure 1 shows the construction of the recombinant plasmid pSET52-ia for the ist-acyB2 gene;

[0025] Figure 2 shows the PCR verification of the integration of the isovaleryl spiramycin I gene into the chromosome of the bacteria producing isovaleryl spiramycin I; where: M—DNA Marker 111; 1—WSJ-2 control bacteria; 2-5—WSJ-IA 1-4 transformants;

[0026] Figure 3 shows the HPLC analysis of isovaleryl spiramycin component I produced by fermentation of the WSJ-IA strain containing the recombinant plasmid pSET52-ia containing the ist-acyB2 gene; where: A—WSJ-2 control strain; B—WSJ-IA is a genetically engineered strain containing the ist gene and the regulatory gene acyB2; SP—spiramycin; ISO-SP—isovaleryl spiramycin I. Detailed Implementation

[0027] The following examples are only intended to help those skilled in the art better understand the present invention, and are not intended to limit the present invention in any way.

[0028] Example 1: Construction of the recombinant plasmid pSET52-ia containing the istacyB2 double gene

[0029] From the recombinant plasmid PSW4 [Shang Guangdong et al., Chinese Journal of Biotechnology 1999, 15(2): 171] previously constructed in our laboratory, we digested it with Smal-BamHI to obtain a 1820bp fragment containing the complete ist gene and the upstream part of the acyB2 gene. Using the total DNA of *Streptomyces thermotolarences* CGMCC4.1501 provided by the China General Microbiological Culture Collection Center as a template, primers were designed based on the acyB2 sequence published by NCBI.

[0030] pi: CGCTCAGGGACGCAAGACC and P2:

[0031] CCGGAATTCGCCCCGTGACCTCACCGTC, PCR reaction was performed under the following conditions: 94°C, pre-denaturation for 2 min; 94°C for 30 s, 60°C for 30 s, 72°C for 1 min, 28 cycles; extension at 72°C for 5 min. A 1013 bp fragment downstream of the acyB2 gene was obtained. The PCR product was digested with BamHI-EcoRI to obtain a 934 bp fragment. The above SmaI-BamHI (1820 bp) × BamHI-EcoRI (934 bp) fragment was ligated into the SmaI-EcoRI restriction site of the pBluesript II KS(+) vector (Merck) to obtain the recombinant plasmid pBKS-ia containing the acyB2 gene and the complete acyB2 gene. The integrated pSET152 plasmid [Bierman M. et al Gene 1992, 116, 43-49, from the gene bank shared resource www.genecool.com] was ligated into the E. coli / Streptomyces conjugation transfer plasmid via the Xbal-EcoRI restriction site to obtain the stacyB2 gene recombinant plasmid pSET52-ia (experimental methods were performed according to the operating procedures of Takara Bio Engineering (Dalian) Co., Ltd.). The construction process is shown in Figure 1.

[0032] Example 2: Recombinant plasmid pSET52-ia was transformed into isovalerylspiramycin I-producing bacterium WSJ-2.

[0033] The isovalerylspiramycin I-producing bacterium WSJ-2 was constructed in our laboratory [Chunyan Ma et al. Current Microbiology, 2011, 62: 16-20]. The strain described in [Chunyan Ma et al. Current Microbiology, 2011, 62: 16-20] was cultured on slant agar [soybean meal 2.0%, glucose 1.0%, starch 3.0%, CaCO3 0.5%, NaCl 0.4%, agar 2.0%] at 28 °C for 7-10 days, following the literature...

[0034] The method described in [DAHopwood et al., Genetic manipulation of Streptomyces, A Laboratory Manual, Norwich; John Innes Foundation UK, 1985] for preparing protoplasts involves: cutting off a piece of bacterial culture, inoculating it into sucrose-containing R2YE medium, and culturing it at 28 °C for 2-4 days; transferring the culture medium at a 10% inoculum level, adding 0.5% glycine, culturing for 20 hours, collecting the mycelium by centrifugation, washing it 2-3 times with 10.3% sucrose solution, lysing it in P solution containing 2 mg / ml lysozyme at 37 °C for 15-60 minutes, and obtaining protoplasts by filtration through cotton. To overcome the restrictive modification effect of exogenous genes on the isovalerylspiramycin I-producing bacterium WSJ-2, this invention first transforms the recombinant plasmid pSET52-ia into methylation-deficient Escherichia coli E. colil 2567 [Mac Neil et al. Genetic manipulation of Streptomyces, A Laboratory Manual, Norwich; John Innes Foundation UK, 1985]. [1992, 111, 61-68], from a genecool shared resource www.genecool.com. Plasmid DNA was extracted from transformants, then transformed into protoplasts under PEG-mediated transformation, and plated on R2YE solid medium. After culturing at 28°C for 24 hours, the culture was covered with a solution containing apopramine to a final concentration of 50 μg / mL. Culture was continued for 7-10 days, and resistant transformants were selected. After continuous subculturing without drug administration, followed by drug administration testing, WSJ-IA, a strain stably expressing resistant isovalerylspiramycin I containing the recombinant plasmid pSET52-ia, was obtained.

[0035] Primers P3: GAGGTAGAAGGCGAAGGT and P4: CGTCAGATGCCAGTTCAC were designed upstream of the ist gene and downstream of the acyB2 gene. PCR was performed using total DNA from the control strain WSJ-2 and four transformants of the present invention WSJ-IA as templates. The PCR reaction program was: 94°C pre-denaturation for 2 min; 94°C for 30 s, 60°C for 30 s, 72°C for 2 min, 28 cycles; 72°C extension for 5 min (Figure 2). The results showed that a 1733 bp PCR product was obtained from the WSJ-IA genome, while no PCR product was obtained from the control strain, indicating that the ist-acyB2 gene had been successfully integrated into the genome of the target strain. The strain was deposited on June 25, 2010, at the China General Microbiological Culture Collection Center, No. 3, Beichen West Road, Chaoyang District, Beijing, with accession number [accession number missing].

[0036] No. CGMCC 3942, classified as Streptomyces spiramyceticus.

[0037] Example 3: Identification and Confirmation of Characteristics of WSJ-IA Strains

[0038] This invention refers to "Classification and Identification of Actinomycetes" [edited by Yan Xunchu, 1992], and identifies and confirms the characteristics of the WSJ-IA strain.

[0039] 1. Morphological and physiological-biochemical characteristics of WSJ-IA culture

[0040] (1) Cultivation characteristics

[0041] The colors of aerial hyphae, intramural hyphae, and soluble pigments of the strain were observed in different culture media. The results are shown in Table 1.

[0042] (2) Microscopic features:

[0043] The spore filaments are flexible, hooked, and spiral; the spores are cylindrical and elliptical.

[0044] Culture characteristics of WSJ-IA strain

[0045] Appendix: Czapek's medium: 30 g sucrose, 3.0 g NaNO3, 0.5 g MgSO4·7¾O, 0.5 g KCl, 1.0 g FeSO4·4H2O, 1.0 g K2HPO4, 15.0 g agar, 1.0 liter distilled water, pH 6.0-6.5.

[0046] Glucose-asparagine medium: 10 g glucose, 0.5 g asparagine, 0.5 g K2HPO4, 15.0 g agar, 1.0 L distilled water, pH 7.2-7.4.

[0047] Glycerol-asparagine medium: 10 g glycerol, 0.5 g asparagine, 0.5 g K2HP4, 15.0 g agar, 1.0 L distilled water, pH 7.2-7.4.

[0048] Inorganic salt starch medium: 10.0 g soluble starch, 1.0 g MgSO4·7H2O, 1.0 g NaCl, 2.0 g (NH4)2SO4, 2.0 g CaCO3, 1.0 g K2HPO4, 10 mg MnCl2·4H2O, 10 mg FeSO4, 10 mg ZnSO4·7H2O, 15.0 g agar, 1.0 L distilled water, pH 7.2.

[0049] ISP-2 medium: 4.0 g yeast extract, 10.0 g malt extract, 4.0 g glucose, 20.0 g agar, 1.0 liter distilled water, pH 7.2-7.4.

[0050] Oat flour culture medium: 20.0 g oat flour, 1 mL microsalt solution, 15 g agar, 1.0 L distilled water, pH 7.2. Note: Microsalt solution: 0.1 g FeSO4·7H2O, 0.1 g MnCl2·4H2O, 0.1 g ZnSO4·7H2O, 100 mL distilled water.

[0051] Gao's No. 1 culture medium: soluble starch 20.0 g, KNO 31.0 g, K2HPO 40.5 g,

[0052] 0.5 g MgSO4·7¾O, 0.5 g NaCl, 0.01 g FeSO4·7¾O, 15.0 g agar, 1.0 liter distilled water, pH 7.2-7.4.

[0053] Santaybromide medium: K2PO 40.5 g, MgSO4·7H2O 0.5 g, citric acid 2.0 g, ferric ammonium citrate 0.05 g, glycerol 60 mL, asparagine 4.0 g, agar 15.0 g, distilled water 1.0 L, pH 7.4.

[0054] (3) Physiological and biochemical characteristics:

[0055] A. Detect the carbon source utilization of WSJ-IA strain on the selected basal culture medium.

[0056] Basic culture medium: (NH4)2SO4 2.0 g, MgSO4·7H2O 0.2 g, aH2PO4·H2O 0.5 g, CaCl2·2H2O 0.1 g, K2HPO4 0.5 g, distilled water 1.0 liter. The carbon source to be tested was added to the basic culture medium at concentrations of 0.1%-0.5%. After sterilization, the culture medium was inoculated with bacterial suspension and cultured at 28°C. Three generations were continuously transplanted, and the carbon source utilization of the WSJ-IA strain was determined by the bacterial growth.

[0057] B. Determination of malonic acid utilization using the basal culture medium: 1.0 g yeast extract, 2.0 g (NH4)2SO4, 0.6 g K2HPO4, 0.4 g KH2PO4, 2.0 g NaCl, 3.0 g sodium malonate, 0.025 g bromothymol blue, 1.0 liter distilled water, pH 7.0-7.4. After sterilization, inoculate with the bacterial suspension and incubate at 28°C for 1-2 days. The culture medium will change from green to blue. The colored substance is malonic acid.

[0058] C. Determination of tartrate utilization using basal culture medium: 10.0 g peptone, 5.0 g NaCl, 10.0 g sodium tartrate, 12.5 mL bromothymol blue (0.2%), 1.0 L distilled water, sterilized. Simultaneously prepare a saturated lead acetate solution. After inoculation of the bacterial suspension, incubate at 28°C for 14 days. Add an equal volume of lead acetate reagent. A greenish-yellow color with a small amount of lead acetate precipitate indicates tartrate utilization.

[0059] D. Gelatin Liquefaction: The basal culture medium consists of 5.0 g peptone, 100-150 g gelatin, and 1.0 liter distilled water, pH 7.2-7.4, sterilized. Take a bacterial culture that has grown for 18-24 hours, puncture it into the gelatin medium, and include an uninoculated control. Incubate at 20°C for 2, 7, 10, 14, and 30 days. Observe bacterial growth and gelatin liquefaction at room temperature below 20°C. A negative result indicates that bacteria have grown, the gelatin surface is free of depressions, and the gelatin forms a stable curd.

[0060] E. Milk reaction: Boil fresh milk and refrigerate overnight. Take the skim milk from the bottom layer. Soak 2.5 g of litmus in 100 ml of distilled water overnight, filter, and take 4 ml of 2.5% litmus solution and 100 ml of skim milk. Dispense into test tubes about 4 cm high, sterilize, and inoculate with strain 28Ό for 1, 3, 5, 7, 14 and 30 days. The results show that the milk curdles and peptones.

[0061] F. Nitrate Reduction: Culture medium: 1.0 L meat bouillon medium, 1.0 g KNO3, pH 7.0-7.6. Dispense 4-5 mL into each tube and sterilize. Griess' reagent: a) 0.5 g p-aminobenzenesulfonic acid, 150 mL dilute acetic acid (10%); b) 0.1 g α-naphthylamine, 20 mL distilled water, 150 mL dilute acetic acid (10%). Diphenylamine reagent: 0.5 g diphenylamine dissolved in 100 mL concentrated sulfuric acid, diluted with 20 mL distilled water. Inoculate the bacterial culture into nitrate medium and incubate at 28°C for 1, 3, and 5 days. Pour a small amount of the culture solution from days 1, 3, and 5 into a clean tube, and add one drop of solution a) and b) to each. The solution turns red, indicating that nitrate has been reduced to nitrite. Adding one drop of diphenylamine reagent does not produce a blue reaction.

[0062] G. Tyrosinase: The strain was inoculated into Gao's No. 1 liquid medium and cultured at 28°C for 7, 9, and 12 days. 2 ml of culture medium was taken from each culture, centrifuged, and the supernatant was collected. 2 ml of phosphate buffer (pH 5.9) and 1 ml of 0.04% tyrosine solution were added, and the mixture was incubated at 37°C for 5 minutes. No red reaction was observed.

[0063] H. Amylase: Inoculate the bacterial strain into meat gravy peptone on agar medium containing 0.2% soluble starch and incubate at 28°C for 2-5 days. After the colonies form distinct colonies on the agar plate, add iodine solution (1.0 g iodine, 2.0 g potassium iodide, 300 ml distilled water) to the plate. A clear zone that does not change color appears around the colonies, indicating that the starch has been hydrolyzed.

[0064] The physiological and biochemical characteristics of WSJ-IA strain are shown in Table 2.

[0065] 2. Molecular systematics analysis of WSJ-IA

[0066] (1) 16S rDNA gene sequence:

[0067] 16S rDNA is a component of bacterial ribosomes, and the 16S rDNA gene is a gene on the bacterial chromosome that encodes rRNA. The corresponding DNA sequence, due to its high degree of conservation in genetics, has been recognized as one of the characteristics of bacterial molecular taxonomy.

[0068] The following 16S rDNA primers were used: 5,-AGAGTTTGATCMTGGCTCAG-3,

[0069] 5, -GGTTACCTTGTTACGACTT-3 '

[0070] Using total DNA from WSJ-IA strain as a template, the PCR reaction program was as follows: pre-denaturation at 96 °C for 1 min; in each cycle, denaturation at 96 °C for 30 s, annealing at 50 °C for 30 s, extension at 72 °C for 1.5 min, for 25 cycles; extension at 72 °C for 10 min to obtain a 1393 bp sequence listing (1).

[0071] Physiological and biochemical characteristics of WSJ-IA strain

[0073] Comparison of WSJ-IA 16S rDNA gene sequence with known bacteria

[0074] This invention also sequenced five commonly used housekeeping genes in Streptomyces molecular taxonomy—atpD, gyrB, rpoB, recA, and trpB—in the WSJ-IA strain. These genes are single-copy and protein-encoding genes with stable sequence structures, exhibiting no gaps or overlaps. Therefore, the sequencing results can be directly used for interspecies comparisons at the nucleotide and amino acid levels to further determine the taxonomic position of WSJ-IA.

[0075] (2) Household genes

[0076] A. atpD gene sequence

[0077] The atpD gene is a subunit of ATP synthase, exhibiting high stability and universality across microbial species, making it suitable as a molecular marker for phylogenetic classification. This invention utilizes the following primers:

[0078] 5' -GTCGGCGACTTC ACC AAGGGC AAGGTGTTC AACACC-3' 5' -GTGAACTGCTTGGCGACGTGGGTGTTCTGGGAC AGGAA -3' Using total DNA from WSJ-IA strain as a template, the PCR reaction program was as follows: 96 °C pre-denaturation for 1 min; denaturation at 96 °C for 30 s, annealing at 63 °C for 30 s, and extension at 72 °C for 1.0 min in each cycle, for 28 cycles; 72 °C extension

[0079] 10 mine obtained a 680bp sequence list (2).

[0080] B. gyrB gene sequence

[0081] gyrB is a subunit of a DNA gyrase tetramer, belonging to type II prokaryotic DNA topoisomerases. It regulates the topological structure of DNA through DNA cleavage and rejoining. It is associated with the resistance of some antibiotic-producing bacteria and has high stability and universality in microbial species, making it suitable as a molecular marker for phylogenetic classification. Therefore, its sequence has been recognized as one of the characteristics of bacterial molecular taxonomy.

[0082] The following primers are used in this invention:

[0083] 5, -GAGGTCGTGCTGACCGTGCTGC ACCGCGGGCGGC AAGTTCGGC-3'

[0084] Using total DNA from WSJ-IA strain 5'-GTTGATGTGCTGGCCGTCGACGTGAGCGTCCGCCAT-3' as a template, the PCR reaction program was as follows: pre-denaturation at 96 °C for 1 min; denaturation at 96 °C for 30 s, annealing at 65 °C for 30 s, extension at 72 °C for 1.5 min in each cycle, for 28 cycles; extension at 72 °C for 10 min to obtain a 1177 bp sequence listing (3).

[0085] C. rpoB gene sequence

[0086] rpoB is a β-subunit of RNA polymerase that is widely distributed in Streptomyces.

[0087] The present invention uses the following primers:

[0088] 5,-GAGCGCATGACCACCCAGGACGTCGAGGC-3'

[0089] 5'-CCTCCGTAGTTGTGACCCTCCCACGGCATGA-3'

[0090] Using total DNA from WSJ-IA strain as a template, the PCR reaction program was as follows: pre-denaturation at 96 °C for 1 min; denaturation at 96 °C for 30 s, annealing at 65 °C for 30 s, and extension at 72 °C for 1.30 min in each cycle, for 28 cycles; extension at 72 °C... 10 min. 870bp sequence list obtained (4).

[0091] D. recA gene sequence

[0092] RecA is a recombinase that plays a crucial role in DNA homologous recombination and the repair of damaged DNA. The presence of RecA is essential for ensuring the structural stability of bacterial genomic DNA; therefore, its sequence is widely recognized as a characteristic of bacterial molecular taxonomy.

[0093] The following primers are used in this invention:

[0094] 5,-CCGCRCTCGCACAGATTGAACGSCAATTC-3'

[0095] 5'- GCSAGGTCGGGGTTGTCCTTSAGGAAGTTGCG -3'

[0096] Using total DNA from WSJ-IA strain as a template, the PCR reaction program was as follows: pre-denaturation at 96 °C for 1 min; denaturation at 96 °C for 30 s, annealing at 60 °C for 30 s, and extension at 72 °C for 1.0 min in each cycle, for 28 cycles; extension at 72 °C...

[0097] 10 min. A 701 bp sequence list was obtained (5).

[0098] E. trpB gene sequence

[0099] The trpB gene encodes tryptophan synthase, which is involved in the primary metabolism of Streptomyces and is considered to be species-specific. Its sequence has been recognized as one of the characteristics of bacterial molecular taxonomy.

[0100] The following primers are used in this invention:

[0101] 5'-TCGATGGCCGGGATGATGCCCTCGGTGCGCGACAGCAGGC -3' Using total DNA from WSJ-IA strain as a template, the PCR reaction program was as follows: 96 °C pre-denaturation for 1 min; in each cycle, denaturation at 96 °C for 30 s, annealing at 66 °C for 30 s, and extension at 72 °C for 1.0 min, for 28 cycles; 72 °C extension...

[0102] 10 min. Obtained 61 1bp sequence list (6).

[0103] The results in Tables 3 and 4 show that the 16S rDNA and five housekeeping gene sequences of strain WSJ-IA are not completely identical to the gene sequences of known strains. Therefore, it is judged that WSJ-IA may be a new species of Streptomyces.

[0104] Comparison of WSJ-IA housekeeping gene sequence with known bacteria

[0105] tus tus

[0106] rpoB S.avermitilis S.avermitilis 94 93 BA000030 NP_826091 MA-4680 MA-4680

[0107] recA S.avermitilis S.avermitilis 91 95 BA000030 NP— 823668 MA-4680 MA-4680

[0108] trpB S.griseus S.flavogriseus ATCC 92 99 AP009493 ZP— 05806307 subsp.griseus 33331

[0109] NBRC 13350

[0110] Note: S: Streptomyces

[0111] Example 3: Potency Detection of Pilot-Scale Fermentation of WSJ-IA Strains

[0112] The WSJ-IA strain was cultured on the slant medium described in Example 2 at 28°C for 7-10 days. A piece was then inoculated onto seed culture medium (1.5% soybean meal, 3.0% starch, 0.4% NaCl, 0.5% CaCO3, 0.3% fish peptone).

[0113] KH₂PO₄ 0.05% was cultured at 28°C for 48 hours in the first stage, then transferred to a second stage seed culture at 28°C for 24 hours, then transferred to a 50L seed tank for 36 hours, and finally transferred to a 2-ton fermenter. The fermentation medium consisted of glucose 0.5%, starch 6.0%, yeast powder 0.5%, fish meal 2.0%, NH₄NO₃ 0.6%, NaCl 1.0%, CaCO₃ 0.5%, and KH₂PO₄ 0.05%.

[0114] Fermentation was carried out at 28 °C for 96 hours with 0.1% MgSO4. The supernatant was collected by centrifugation of the fermentation broth and then diluted with a pH solution containing 3% NaCl.

[0115] Dilute with 7.8–8.0 g phosphate buffer. Bacillus [CGMCC(B)63501] was used as the test bacterium. The culture medium formulation was: 0.6% peptone, 0.15% beef extract, 0.6% yeast extract, 0.2% glucose, and 1.5–2.0% agar. The fermentation titer was calculated using the standard curve method described in Appendix XI A of the 2010 edition of the Chinese Pharmacopoeia, with acetylspiramycin as the standard. In this experiment, repeated three times, the average fermentation titer of the WSJ-IA strain was 1160 μg / mL, while the average fermentation titer of the WSJ-2 strain (containing the ist single gene) control was 280 μg / mL (Table 5).

[0116] Example 4: Detection of Isovaleryl Spiramycin I Component Produced by Fermentation of WSJ-IA Strain

[0117] The fermentation broth obtained in Example 3 was sampled and the pH was adjusted to 8.5. It was then extracted with an equal volume of ethyl acetate, and the ethyl acetate extract was concentrated to dryness and dissolved in methanol. Kromasil C was used for the extraction. 18 Column (4.5 mm x 150 mm, 5 μm); Mobile phase: Methanol: Sodium dihydrogen phosphate solution (v / v 53:47); Detection wavelength: 231 nm ; Flow rate: 1.0 mL Tnin; column temperature: 25 °C; injection volume: 10-20 μL. The content of isovalerylspiramycin I fraction in the product was calculated by HPLC detection.

[0118] (Figure 2) The results of three experiments showed that the WSJ-IA strain produced an average total isovaleryl spiramycin I content of 12.061%, while the WSJ-2 strain containing the isid single gene produced a total isovaleryl spiramycin I content of 7.088%.

[0119] Example 3: Fermentation culture was conducted, and the fermentation titers of the two strains were determined by microbial methods. The ethyl acetate extract was analyzed by HPLC (Figure 3). The production of isovalerylspiramycin I was compared based on the peak area in the HPLC results, and the ratio of isovalerylspiramycin I to spiramycin produced by each strain was calculated. The results showed that the introduction of the ist-acyB2 gene increased the fermentation titer of the WSJ-IA strain by 414% and increased the isovalerylspiramycin I content by 170.2%. Correspondingly, the production of spiramycin was reduced, and the ratio of isovalerylspiramycin I component to spiramycin was increased by 218% (Table 5).

[0120] This invention provides a strain containing the isist-acyB2 gene that produces isovaleryl spiramycin I. Under certain fermentation conditions, this strain produces isovaleryl spiramycin I with a 1.7-fold higher content and a 4.14-fold higher fermentation titer compared to strains containing only the isist gene. Table 5 compares the fermentation titer and component content of WSJ-IA and WSJ-2 strains.

Claims

Claims 1. A genetically engineered bacterium with high content and high yield of isovalerylspiramycin I component, characterized by: The genetically engineered bacterium is a clone strain co-expressed in the isovaleryltransferase gene ist and the acyB2 regulatory gene in the isovalerylspiramycin I-producing bacterium WSJ-2.

2. A method for constructing the genetically engineered bacteria of claim 1, characterized in that: A) Using total DNA from thermostable Streptomyces (StreptoOT t / zer oto / arewc CGMCC4.1501) as a template, primers were designed based on the ist-acyB2 sequence published by NCBI. The ist-aCyB2 linked gene fragment was obtained by PCR. An appropriate restriction enzyme site was added to it. Alternatively, the ist and acyB2 gene fragments can be ligated to an integrative vector that can be transformed into isovalerylspiramycin I producing bacteria through appropriate restriction enzyme sites to obtain a recombinant plasmid containing the ist-acyB2 gene. B) The recombinant plasmid containing isist-acyB2 was transformed into isovaleryl spiramycin I producing strain WSJ-2. After the transformants were obtained by resistance screening, they were continuously passaged without drug addition. After drug addition, the strain stably expressing isovaleryl spiramycin I producing strain containing the recombinant plasmid was obtained and named WSJ-IA, strain preservation number CGMCC No3942.

3. The method for constructing the genetically engineered bacteria according to claim 2, characterized in that, The obtained WSJ-IA strain was verified by PCR to contain the ist-acyB2 sequence at the gene level.

4. The method for constructing the genetically engineered bacteria according to claim 2, characterized in that: After culturing and fermenting, the fermentation titer of WSJ-IA strain was calculated, and the fermentation titer of WSJ-IA strain was not less than 1160 μg / mL, and the total content of isovalerylspiramycin I produced was not less than 12.061%.